ACM
FULC icon

Altium Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Altium Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-111,812
Closed -$526K – 45
2024
Q4 		$526K Buy
+111,812
New +$412K 0.15% 58
2021
Q3 		– Sell
-213,533
Closed -$2.24M – 133
2021
Q2 		$2.24M Buy
+213,533
New +$2.16M 0.52% 77

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Altium Capital Management's FULC Position: Q1 2025 in Review

Altium Capital Management sold out of Fulcrum Therapeutics (FULC) in Q1 2025, closing a stake of 111,812 shares — an estimated $526K sold.

Altium Capital Management first reported a position in FULC in Q2 2021 and held it in 2 quarters. The position peaked at $2.24M in Q2 2021. 117 funds tracked by Wall St. Rank hold FULC as of Q1 2025.

  • Altium Capital Management reported no remaining Fulcrum Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Altium Capital Management sold 111,812 Fulcrum Therapeutics shares in Q1 2025, an estimated $526K.
  • Altium Capital Management first reported a position in Fulcrum Therapeutics in Q2 2021 and held it in 2 quarters.
  • Altium Capital Management's Fulcrum Therapeutics position peaked at $2.24M in Q2 2021.
  • 117 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.